Literature DB >> 35657565

The fluorescence amplification strategy based on 3D DNA walker and CRISPR/Cas12a for the rapid detection of BRAF V600E.

Wenxiu Zhang1, Shuhui Zhao1, Zuowei Xie1, Siyi Chen1, Yuqi Huang1, Zixin Zhao1, Gang Yi2.   

Abstract

Circulating tumor DNA (ctDNA) is a fragment of single- or double-stranded DNA originating from tumor or circulating tumor cells and provides accurate information regarding the molecular characteristics of tumors. Therefore, sensitive detection of ctDNA is of great significance to mutation analysis and clinical diagnosis. Among various ctDNAs, the BRAF V600E is related to aggressive behavior, disease recurrence, and disease-specific mortality in papillary thyroid carcinoma. Herein, we selected the BRAF V600E gene sequence as an in vitro biomarker, and established a fluorescence detection strategy combined 3D DNA walker with CRISPR/Cas12a. In the presence of the target ctDNA, 3D DNA walker could identify and bind it, and thus released a large amount of output DNAs through cyclic cleavage with the assistance of specific endonuclease (Nb.BbvCI). The output DNAs were specifically bound to crRNA and activated the non-specific trans-cleavage activity of Cas12a. Finally, the fluorescence signal was significantly enhanced. Notably, this method can detect the BRAF V600E in a range of 1 fM ~ 20 nM with a detection limit of 0.37 fM without DNA polymerase. Due to the powerful amplification capability of 3D DNA walker and high specificity and programmability of CRISPR/Cas12a, the entire process took only a maximum of 70 min. Furthermore, it can be potentially used for the detection of ctDNA in human serum. In summary, this method not only provides a platform for the rapid detection of ctDNA, but also shows good potential for early clinical diagnosis and biomedical research.
© 2022. The Author(s), under exclusive licence to The Japan Society for Analytical Chemistry.

Entities:  

Keywords:  3D DNA walker; CRISPR/Cas12a; Circulating tumor DNA; Fluorescence

Mesh:

Substances:

Year:  2022        PMID: 35657565     DOI: 10.1007/s44211-022-00131-5

Source DB:  PubMed          Journal:  Anal Sci        ISSN: 0910-6340            Impact factor:   1.967


  37 in total

Review 1.  Liquid Biopsy-Based Biomarkers of Treatment Response and Resistance.

Authors:  Elaine Kilgour; Dominic G Rothwell; Ged Brady; Caroline Dive
Journal:  Cancer Cell       Date:  2020-04-13       Impact factor: 31.743

2.  Biochemical and molecular characterization of the novel BRAF(V599Ins) mutation detected in a classic papillary thyroid carcinoma.

Authors:  S Moretti; A Macchiarulo; V De Falco; N Avenia; F Barbi; C Carta; A Cavaliere; R M Melillo; L Passeri; F Santeusanio; M Tartaglia; M Santoro; E Puxeddu
Journal:  Oncogene       Date:  2006-02-27       Impact factor: 9.867

3.  Association between BRAF V600E mutation and recurrence of papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; Young Kee Shong; Tae Yong Kim; David Viola; Rossella Elisei; Bela Bendlová; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Roderick Clifton-Bligh; Giovanni Tallini; Elizabeth H Holt; Vlasta Sýkorová
Journal:  J Clin Oncol       Date:  2014-10-20       Impact factor: 44.544

Review 4.  Deoxyribozymes: selection design and serendipity in the development of DNA catalysts.

Authors:  Scott K Silverman
Journal:  Acc Chem Res       Date:  2009-10-20       Impact factor: 22.384

Review 5.  Cell-free circulating tumour DNA as a liquid biopsy in breast cancer.

Authors:  Leticia De Mattos-Arruda; Carlos Caldas
Journal:  Mol Oncol       Date:  2015-12-17       Impact factor: 6.603

6.  Mutation analysis of the BRAF codon 599 in malignant pleural mesothelioma by enriched PCR-RFLP.

Authors:  Hideaki Dote; Kazunori Tsukuda; Shinichi Toyooka; Masaaki Yano; Harvey I Pass; Nobuyoshi Shimizu
Journal:  Oncol Rep       Date:  2004-02       Impact factor: 3.906

7.  Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer.

Authors:  Mingzhao Xing; Ali S Alzahrani; Kathryn A Carson; David Viola; Rossella Elisei; Bela Bendlova; Linwah Yip; Caterina Mian; Federica Vianello; R Michael Tuttle; Eyal Robenshtok; James A Fagin; Efisio Puxeddu; Laura Fugazzola; Agnieszka Czarniecka; Barbara Jarzab; Christine J O'Neill; Mark S Sywak; Alfred K Lam; Garcilaso Riesco-Eizaguirre; Pilar Santisteban; Hirotaka Nakayama; Ralph P Tufano; Sara I Pai; Martha A Zeiger; William H Westra; Douglas P Clark; Roderick Clifton-Bligh; David Sidransky; Paul W Ladenson; Vlasta Sykorova
Journal:  JAMA       Date:  2013-04-10       Impact factor: 56.272

8.  High prevalence of BRAF gene mutation in papillary thyroid carcinomas and thyroid tumor cell lines.

Authors:  Xiulong Xu; Roderick M Quiros; Paolo Gattuso; Kenneth B Ain; Richard A Prinz
Journal:  Cancer Res       Date:  2003-08-01       Impact factor: 12.701

9.  Metabolic Fingerprinting Links Oncogenic PIK3CA with Enhanced Arachidonic Acid-Derived Eicosanoids.

Authors:  Nikos Koundouros; Evdoxia Karali; Aurelien Tripp; Adamo Valle; Paolo Inglese; Nicholas J S Perry; David J Magee; Sara Anjomani Virmouni; George A Elder; Adam L Tyson; Maria Luisa Dória; Antoinette van Weverwijk; Renata F Soares; Clare M Isacke; Jeremy K Nicholson; Robert C Glen; Zoltan Takats; George Poulogiannis
Journal:  Cell       Date:  2020-06-18       Impact factor: 41.582

10.  Plasma Circulating Tumor HPV DNA for the Surveillance of Cancer Recurrence in HPV-Associated Oropharyngeal Cancer.

Authors:  Bhishamjit S Chera; Sunil Kumar; Colette Shen; Robert Amdur; Roi Dagan; Rebecca Green; Emily Goldman; Jared Weiss; Juneko Grilley-Olson; Shetal Patel; Adam Zanation; Trevor Hackman; Jeff Blumberg; Samip Patel; Brian Thorp; Mark Weissler; Wendell Yarbrough; Nathan Sheets; William Mendenhall; Xianming M Tan; Gaorav P Gupta
Journal:  J Clin Oncol       Date:  2020-02-04       Impact factor: 44.544

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.